Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
USPs of Gastrointestinal API
- Customized Particle Size Distribution
- Multiple manufacturing units
- High degree of supply assurance
- Vertically Integrated
- Manufacture capacity of 100 multi-tones of prazole APIs
- Supplier to 50 pharma companies across more than 25 countries for Gastrointestinal APIs.
- Well-positioned to meet the global demand for high quality Prazole APIs
- Active DMFs in all key markets
- Proven track record as strong player in Prazole family both as APIs and Finished formulations
- Multiple PSD Specs in place with validated size reduction process
- Nitrosamine impurities assessment reports available
- Meets Pharmacopeia requirements for US, EU, China, and Japan
- Manufacturing and supply chain assurance
- Favorable IP
Gastrointestinal API Products Manufacturer and Supplier
Dr. Reddy's offers a wide selection of Gastrointestinal APIs in the class of molecules that include - Proton pump inhibitors, H2-receptor antagonists, 5-HT3 receptor antagonists, laxatives, etc. We have established leaders in the GI therapeutic area, i.e., Proton pump inhibitors and the market leaders in the Prazole franchise APIs. As a Gastrointestinal API manufacturer and Gastrointestinal API supplier, Dr. Reddy's manufactures large volumes of gastrointestinal APIs consistently to cater to global demand and can offer a customized particle size distribution to meet our customer formulation needs.
- Proton Pump Inhibitors
- Anti-emetics
- Anti-constipation
- H2-receptor antagonists
- PBC
- Non-alcoholic steatohepatitis
PPIs- inhibit the proton (H+-K+–ATPase) pump of the parietal cells in the stomach. Anti-emetics - blocks specific receptors that respond to neurotransmitter molecules, such as serotonin, dopamine & histamine. H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells.
- The global pandemic COVID-19 has positively affected the global gastrointestinal drug market share.
- Owing to the increasing cases of gastric diseases, huge investments have been made by manufacturers for the development of gastrointestinal treatment.
- The market share for GTI drugs is expected to grow in the coming years.
The global gastrointestinal drugs market is expected to grow from $46.68 billion in 2020 to $48.74 billion in 2021 at a CAGR of 4.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during COVID-19.
Used to treat people with heartburn, stomach or intestinal ulcers, or excess stomach acid. Proton pump inhibitors reduce acid by shutting down the tiny pumps within cells in your stomach that secrete it.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。
Let’s talk API sourcing live at
Tackle sourcing bottlenecks and compliance hurdles